Amgen and Immunomedics Announce Emphasis On Development Of AMG 412 (Epratuzumab) As Combination Therapy While Closing Single Agent Trial Read more about Amgen and Immunomedics Announce Emphasis On Development Of AMG 412 (Epratuzumab) As Combination Therapy While Closing Single Agent Trial
J&J Ordered To Pay Amgen's Costs and Attorneys' Fees In Recent Arbitration Read more about J&J Ordered To Pay Amgen's Costs and Attorneys' Fees In Recent Arbitration
Enbrel is First Biologic to Receive FDA Approval for the Treatment of Ankylosing Spondylitis Read more about Enbrel is First Biologic to Receive FDA Approval for the Treatment of Ankylosing Spondylitis
New Data Suggest Risk of Infection Doubles with Reduced NEUPOGEN Administration Read more about New Data Suggest Risk of Infection Doubles with Reduced NEUPOGEN Administration
Amgen Announces First Annual Recipient of the Amgen Prize for Therapeutic Advances in Nephrology Read more about Amgen Announces First Annual Recipient of the Amgen Prize for Therapeutic Advances in Nephrology
Epogen - Important Prescribing Information Read more about Epogen - Important Prescribing Information
Federal Appeals Court Affirms TKT Infringement; Remands Certain Validity Issues to Lower Court Read more about Federal Appeals Court Affirms TKT Infringement; Remands Certain Validity Issues to Lower Court
Amgen Announces Webcast Of Fourth Quarter And Full Year 2002 Financial Results Read more about Amgen Announces Webcast Of Fourth Quarter And Full Year 2002 Financial Results
Amgen Announces Positive Results Of Phase 3 Study For rHu-KGF Read more about Amgen Announces Positive Results Of Phase 3 Study For rHu-KGF
Amgen Announces Award for Science Teaching Excellence in King and Snohomish Counties Read more about Amgen Announces Award for Science Teaching Excellence in King and Snohomish Counties
